摘要
目的:探讨和观察茶碱缓释片、布地奈德气雾剂与酮替芬联合治疗儿童哮喘的疗效及其可能存在的不良反应。方法:收治支气管哮喘患儿52例,按5～8mg/(kg·次),口服茶碱缓释片,12小时1次;吸入布地奈德气雾剂100～200μg/次,2～3次/日;酮替芬0.5～1mg/次,每12小时1次。分别在治疗后第3、7、14天观察临床疗效,同时在7天后观察肺通气功能(PEFR)的动态变化,并统计治疗7天,1个月和3个月的PEFR均值达预计值的百分比。结果:治疗第3天,临床症状评分减少68.8±23.2%,治疗第7天,临床症状评分减少91.2±12.4%,治疗第14天,临床症状评分减少97.3±3.2%;治疗1周时临床控制15例(30.5%),显效34例(65.5%),有效3例(5.8%),治疗1及3个月后PEFR比治疗前明显改善(P<0.01)。观察中无1例出现不良反应。结论:茶碱缓释片同时吸入布地奈德气雾剂与酮替芬联合能有效控制支气管哮喘的发作,具有安全,有效不良反应少等优点。
Objective：To explore and observe theophylline,budesonide aerosol and ketotifen efficacy of combined treatment of children with asthma and their possible side effects.Methods：52 cases of bronchial asthma in children,according to every 5～8mg/kg,oral theophylline,12 hours;inhaled budesonide aerosol 100～200μg/times,2 or 3 times a day;ketone ketotifen 0.5～1mg/times,once every 12 hours.Respectively,after 7,14 days in the treatment of clinical observation,while lung function observed after 7 days（PEFR） of the dynamic changes,and statistics for 7 days,1 month and 3-month average of predicted PEFR percentage of.Results：The first 3 days,the clinical symptom score reduction 68.8±23.2%,treatment of 7 days,the clinical symptom score reduction 91.2±12.4%,treatment of the first 14 days,clinical symptom score reduction 97.3±3.2%;treatment 1 week of clinical control in 15 cases（30.5%） were cured,34 cases（65.5%）,effective in 3 cases（5.8%）,treatment of 1 and 3 months after the PEFR significantly improved compared with before treatment（P0.01）.Observed in no case of adverse reactions.Conclusion：of theophylline while inhaled budesonide aerosol and ketotifen joint can effectively control asthma attacks,with safe,effective and less adverse reactions,etc.is worthy of clinical application and popularization.
